These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3023256)

  • 21. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
    Guazzi M; Agostoni P
    Clin Sci (Lond); 1999 Jan; 96(1):17-22. PubMed ID: 9857102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
    Richer C; Fornes P; Domergue V; De Gasparo M; Giudicelli JF
    J Card Fail; 2001 Sep; 7(3):269-76. PubMed ID: 11561229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB; Davies RO; Ferguson RK
    Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.
    Ettinger SJ; Benitz AM; Ericsson GF; Cifelli S; Jernigan AD; Longhofer SL; Trimboli W; Hanson PD
    J Am Vet Med Assoc; 1998 Dec; 213(11):1573-7. PubMed ID: 9838955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure.
    Jiang XJ; O'Rourke MF; Zhang YQ; He XY; Liu LS
    J Hypertens; 2007 May; 25(5):1095-9. PubMed ID: 17414675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
    Todd PA; Heel RC
    Drugs; 1986 Mar; 31(3):198-248. PubMed ID: 3011386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
    Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
    Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
    Bartha E; Kiss GN; Kalman E; Kulcsár G; Kálai T; Hideg K; Habon T; Sumegi B; Toth K; Halmosi R
    J Cardiovasc Pharmacol; 2008 Sep; 52(3):253-61. PubMed ID: 18806606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisinopril, a new angiotensin converting enzyme inhibitor.
    Arzubiaga C; Beck NA
    Am J Med Sci; 1992 May; 303(5):340-4. PubMed ID: 1316080
    [No Abstract]   [Full Text] [Related]  

  • 31. A study of 24-hour ambulatory blood pressure monitoring in cases of intermittent acute porphyria with hypertension: special reference to safety and efficacy of angiotensin-converting enzyme inhibitor (enalapril) therapy.
    Bandyopadhyay M; Gupta BK; Panwar RB; Kabra PK; Kaushik AN; Chadda VS
    Indian Heart J; 2002; 54(6):734. PubMed ID: 12674196
    [No Abstract]   [Full Text] [Related]  

  • 32. Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
    Sethi R; Shao Q; Ren B; Saini HK; Takeda N; Dhalla NS
    Mol Cell Biochem; 2004 Aug; 263(1-2):11-20. PubMed ID: 15524163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure.
    Cody RJ; Laragh JH; Atlas SA; Case DB
    J Hypertens Suppl; 1983 Oct; 1(1):77-84. PubMed ID: 6085835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure.
    Lantz P; Enghoff E; Hedlund A; Hägg A
    Scand J Urol Nephrol Suppl; 1984; 79():129-32. PubMed ID: 6089312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of trandolapril in mild to moderate hypertension--a double blind comparative clinical trial with enalapril in Indian population.
    Shankar PK; Vidyasagar S; Adiga S; Naidu MU; Usha Rani P; Rao D; Bairy KL; Nair S; Jayaprakash B; Shashikiran U; Mukhyapranaprabhu
    Indian J Physiol Pharmacol; 2006; 50(4):421-6. PubMed ID: 17402274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats.
    García-Estañ J; Ortiz MC; O'Valle F; Alcaraz A; Navarro EG; Vargas F; Evangelista S; Atucha NM
    Clin Sci (Lond); 2006 Feb; 110(2):227-33. PubMed ID: 16197366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute renal failure following ACE inhibition in a patient with coarctation of the aorta.
    Sever MS; Sönmez B
    Nephrol Dial Transplant; 1996 Aug; 11(8):1643-4. PubMed ID: 8856229
    [No Abstract]   [Full Text] [Related]  

  • 39. Symposium: Converting enzyme inhibition. New trends in the treatment of hypertension and congestive heart failure. Brussels, Belgium, June 21, 1985.
    Acta Cardiol; 1986; 41(5):329-96. PubMed ID: 3022508
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension.
    Rugale C; Cordaillat M; Mimran A; Jover B
    J Renin Angiotensin Aldosterone Syst; 2005 Dec; 6(3):154-60. PubMed ID: 16525947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.